Intervention

RMC-4630

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions6

Lead sponsors shown2

Clinical trials

4 shown

Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant CancersNCT04916236 · 2022-03-31

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard TherapiesNCT05054725 · 2021-12-30

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLCNCT03989115 · 2019-07-02

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid TumorsNCT03634982 · 2018-09-28

Common conditions

Non-Small Cell Lung Cancer2 Colorectal Cancer1 KRAS Mutation-Related Tumors1 Pancreatic Cancer1 Solid Tumor1 Solid Tumors1

Leading sponsors

Revolution Medicines, Inc.3 The Netherlands Cancer Institute1

Trial status mix

COMPLETED2

TERMINATED1

UNKNOWN1

Phase mix

PHASE13

PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.